

# GPCR MARKERS FOR CANCER RESEARCH

G protein-coupled receptors (GPCRs) allow the communication between the environment and the cell's interior: they transduce extracellular stimuli into intracellular signals. GPCRs play an essential role in different physiological functions and have been well documented in many forms of cancer, contributing to cancer proliferation, angiogenesis, invasion, and metastasis. GPCRs are suitable biomarkers for the early diagnosis of cancer. The pharmacological inhibition of GPCRs and their downstream targets might provide an opportunity for the development of new, mechanism-based strategies for cancer prevention and treatment. In this whitepaper, we highlight the role of some selected GPCRs markers in cancer development and treatment.

## Introduction

G protein-coupled receptors (GPCRs), also known as seven-transmembrane domain (7TM) receptors, belong to a vast family of signaling proteins that mediate cellular responses to most hormones, metabolites, chemokines, and neurotransmitters.

With more than 800 identified members, the human GPCRs gene family remains the largest in mammals, including humans. Among the plethora of functions assigned to these proteins, one could mention mood and affective behavior, cardiovascular regulation, immunity and inflammation, olfaction, and pain <sup>1</sup>.

Among the 800 family members, only four proton-sensing receptors GPR132 (G2A), GPR4, GPR65 (TDAG8), and GPR68 (OGR1), are known to regulate acidity (pH) in the cellular environment <sup>1</sup>. Except for protons, these receptors have no other known ligand and are hence called "orphan".

The GPCRs known so far falls into six classes based on sequence and function:

- Class A: Rhodopsin-like receptors,
- Class B: Secretin family,
- Class C: Metabotropic glutamate receptors,
- Class D: Fungal mating pheromone receptors,
- Class E: cAMP receptors,
- Class F: Frizzled (FZD) and Smoothed (SMO) receptors.

GPCRs constitute the most significant and druggable therapeutic target category <sup>2</sup>, in fact, any pharmaceutical drug in development targets a transmembrane receptor <sup>3</sup>, mainly a GPCR. Finding new ways to modulate GPCR signaling to increase their efficacy and at the same time blocking the adverse effects remains an important and tremendous challenge in pharmaceutical development.

## GPCRs in cancer research

GPCRs are attractive drug targets due to their relevance in a plethora of disease conditions <sup>4</sup>.

Despite a considerable body of information, GPCRs have not presented themselves as a valid "genetic driver" in cancer. Hence GPCRs have remained neglected or at least understudied as molecular targets in oncology.

The past decades have experienced a changed perception towards the role GPCRs in cancers. Today we know that aberrant GPCR expression may contribute to oncogenesis mechanisms, including metastasis, therapy resistance, and immune evasion.

Yet surprisingly, few GPCRs based therapies have found their way to the oncologist at the clinic. Despite recent advancements in the structural and functional knowledge of GPCRs, only eight FDA-approved drugs target GPCRs for cancer therapy <sup>5</sup> (**Table 1**).

Current and future research aim to discover the potential benefits of targeting GPCRs and their signaling circuits for the new era of precision medicine and cancer immunotherapies.

### Cover image:

*Immunofluorescent staining of human cell line A-431 using the Anti-MASL1 (HPA017983) antibody, shows localization to nucleoplasm, plasma membrane & cytosol, in green. Microtubules are shown in red and nuclei in blue.*

The first study of GPCRs and cancer was published in 1986 when a new human oncogene called MAS was noted for its tumorigenicity in nude mice <sup>6</sup>.

This protein was found to be very hydrophobic with seven potential transmembrane domains. In this respect, the structure of the MAS protein was a novelty among cellular oncogene products.

For this reason, MAS constituted an entirely new functional class of oncogenes carrying no oncogenic mutations <sup>6</sup>.

The MAS1 proto-oncogene-like GPCR binds the neuroregulatory peptide angiotensin <sup>7</sup> and is expressed in the testis, breast, cervical, lung, and pancreatic cancers.

The first example of a classical GPCR neurotransmitter receptor with transforming properties was the serotonin 5HT1C-receptor (HTR1C) that, when expressed in mouse fibroblasts, generated sarcomas (tumors) <sup>8</sup>.


The identification of activating mutations in the thyrotropin receptor gene (TSHR) in hyperfunctioning thyroid adenomas provided another evidence that mutant GPCRs could initiate a neoplastic disease <sup>9</sup>.

The muscarinic acetylcholine (mAChRs) family of the GPCR rhodopsin-like receptors subtypes (CHRM1 HPA014101, CHRM2, and CHRM3) reveals oncogenic potential. Ligand-stimulation of mAChRs linked to phosphatidylinositol hydrolysis can act as conditional oncogenes showing the transforming ability of mouse fibroblast <sup>10</sup>.

Like other oncogenes, tumor-generating mutations also occur among GPCRs, such as for the  $\alpha$ -adrenergic receptor 1B (ADRA1B, HPA074416) inducing tumor generation in nude mice <sup>11</sup>.

These early studies presented a new and unexpected role for GPCRs as capable of oncogenic transformation.

More recently, another interesting example of a mutated GPCR turned tumorigenic is the cysteinyl-leukotriene receptor 2 (CysLTR2, HPA046528), which has a single mutation in transmembrane helix 3 (mutant CysLTR2-L129Q), causing uveal melanomas in humans <sup>12</sup>.



**Figure 1. Anti-MAS1L antibody**

Immunohistochemical stainings of human prostate cancer (A) and breast cancer (B) using the **Anti-MAS1L (HPA017983)** polyclonal antibody show moderate positivity in brown.

## Neurohormonal GPCRs


The two members of the bombesin-family of regulatory peptides, gastrin-releasing peptide (GRP) and neuromedin B (NMB), are strongly implicated in cancer development <sup>13,14</sup>. The GRP receptor (GRPR) has higher selectivity for GRP over NMB, whereas the NMB receptor (NMBR) has the reverse pattern.

These GPCR-ligands are highly expressed/produced in different tumors where they act as autocrine or paracrine growth factors. GRPR and NMBR are frequently overexpressed in colorectal tumors, gliomas and lung carcinomas, ovarian epithelial cancers, and neuroendocrine tumors of the gut and lung <sup>15,16</sup>.

Many of the growth stimulatory effects of these GPCRs are mediated through the transactivation of the tyrosine kinase receptors like the EGF and HER2 receptors, belonging to an entirely different class of transmembrane proteins with kinase activity <sup>17</sup>.


Another category of neurohormonal GPCRs involved in cancer is the category of somatostatin receptors SSTR1 and SSTR2, expressed in both small cell (SCLC) and non-small cell lung cancer (NSCLC) <sup>18</sup>.

Radiolabeled SSTR2 analogs are utilized for radiographic imaging of tumors, which, in combination with PET-CT, provides improved lung cancer detection. SSTR2 analogs are also an interesting candidate for targeted chemotherapy and radiotherapy <sup>19,20</sup>.





**Figure 2. Anti-SSTR1 antibody**

Immunohistochemical staining of human stomach using the **Anti-SSTR1 (HPA031506)** polyclonal antibody shows moderate to strong positivity in luminal membrane in glandular cells, in brown.



**Figure 3. Anti-SSTR2 antibody**

Immunofluorescent staining of human cell line A-431 using the **Anti-SSTR2 (HPA007264)** polyclonal antibody shows localization to cytosol, in green. Microtubules are shown in red and nuclei in blue.

**A****B**

**Figure 4. Anti-C2ORF74 antibody.**

Immunohistochemical staining using the **Anti-C2ORF74 (HPA026826)** polyclonal antibody on human skin with squamous cell carcinoma **(A)** and lung adenocarcinoma **(B)**, shows moderate cytoplasmic and membranous positivity, in brown. **(C)** **Anti-C2ORF74 (HPA026826)** immunofluorescent staining of human cell line U-251 MG shows positivity in centrosome & nucleus but not nucleoli.


**Box 1.**  
**GPCR and oncoviruses**


Oncoviruses are cancer-causing viruses. The human hepatitis B (HBV) and C (HCV), the human papillomaviruses (HPV), the Epstein–Barr virus (EBV), and the Kaposi sarcoma herpesvirus (KSHV) are the most important human oncoviruses currently known. Interestingly, some virally encoded and constitutively activated GPCRs promote and sustain tumorigenesis.

An example of GPCR and oncovirus is the “hijacked” GPCR known as KSHV-vGPCR (or ORF74). ORF74 is a highly constitutively active GPCR encoded and expressed by the HHV herpesvirus 8 (HHV8).


ORF74 is involved in the pathogenesis of Kaposi’s sarcoma (a tumorous skin lesion in immunocompromised patients, including those with progressed HIV/AIDS) <sup>21</sup>.

As for the “classical” oncogenes belonging to the kinase category, most were originally identified in retroviruses. The dawn of these studies opened a new door to establish the link between GPCRs and cancers.






**Figure 5. Anti-KNG1 antibody** Immunohistochemical staining of a human thyroid gland affected by follicular adenoma carcinoma using the **Anti-KNG1 (HPA001616)** polyclonal antibody shows moderate cytoplasmic and membranous positivity, in brown.



**Figure 6. Anti-LGR5/GPCR49 antibody** Immunohistochemical staining of human colon using the **Anti-LGR5/GPCR49 (HPA012530)** polyclonal antibody shows cytoplasmic positivity in glandular cells, in brown.



**Figure 7. Anti-TACR1 antibody** Immunohistochemical staining using the **Anti-TACR1 (HPA074573)** polyclonal antibody of human skin affected by squamous cell carcinoma shows high positivity, in brown.

## Rhodopsin-like GPCRs

The neuropeptide Y (NPY) is a neuropeptide that can also regulate the growth of various tumors. The NPY receptors belong to the class A or rhodopsin-like GPCR <sup>22</sup>.

Neuroblastoma and Ewing's sarcoma (two pediatric tumor types) produce high levels of NPY. The hypoxic condition of the tumor microenvironment of these solid cancers upregulates and promotes the Y2R/Y5R NPY signaling axis <sup>23</sup>. By stimulating the cognate receptors, Y2R and Y5R, NPY promotes the survival, migration, and angiogenesis of these neoplasias.

Another category of rhodopsin-like GPCRs involved in cancer is the tachykinin receptors, including the substance P receptor/NK1R/TACR1. Substance P induces tumor cell proliferation, angiogenesis, and cancer cell migration. Moreover, tumor cells frequently overexpress TACR1 (HPA074573).

It is of interest in this context to note that the TACR1 antagonist, Aprepitant, shows promising anti-tumorigenic activity <sup>24</sup>.

## Frizzled GPCRs and Wnt signaling

The frizzled group of GPCRs is evolutionarily conserved and serves to transduce signals from the Wnt-type lipoprotein growth factors. Several cancers display dysregulated Wnt signaling pathways.

Originally defined as a Wnt target gene, potentiating the canonical Wnt/ $\beta$ -Catenin signaling, the Leucine-rich repeat-containing G-protein-coupled receptor 5 (LGR5 or GPR49, HPA012530) represents an exquisitely specific and almost "generic" marker of normal stem cells in several tissues, including the intestine <sup>25</sup>.

LGR5 has been proposed as an independent prognostic marker and as therapeutic target for colorectal cancer, although, in this context, its role appears very complex <sup>26</sup>.

## Adhesion GPCRs

The adhesion G protein-coupled receptors (aGPCRs) constitute a large yet poorly understood family of seven-transmembrane proteins.

There is ample evidence for the implication of tumor-associated adhesion-GPCRs in tumorigenesis. These receptors affect the growth of tumor cells, angiogenesis, tumor cell migration, invasion, and metastasis, either positively or negatively <sup>27</sup>.

Some adhesion-GPCRs are in addition considered potential biomarkers for specific types of cancers.

ADGRG1/GPR56 is upregulated in some colorectal cancer tissues but shows anti-metastatic properties in melanoma via inhibition of cell-extracellular matrix signaling <sup>28,29</sup>.

Another member of the adhesion GPCRs family involved in cancer is the glioma marker ADGRL4 (AMAb91268), which promotes glioblastoma through hypoxia signaling and is considered a target for anti-cancer therapy <sup>30</sup>.


## GPCRs and chemokines

Chemokines are small soluble cytokines that guide the migration of other cell types, particularly immune cells. The chemokines have a plethora of important roles in cancer, not least in association with metastasis and tumor immunity <sup>31</sup>.

Most chemokines act through GPCRs and play critical roles in tumor growth, angiogenesis, invasion, and leukocyte infiltration into the tumor. One example includes CCL2 (HPA019163), a chemokine secreted from tumors acting through its receptor CCR2 to promote prostate tumor growth <sup>32</sup> and stimulates tumor angiogenesis <sup>33</sup>.


Most solid tumor undergoing metastasis does so via lymph nodes. One example is the chemokine (C-C motif) ligand 1 CCL1 (HPA049861) that attracts CCR8-positive distal tumor cells towards the lymph node <sup>34</sup>. Strategies to block the ligand interactions with these GPCR would be of great therapeutic value.

Chemokine/chemokine receptor signaling is also known to regulate tumor immunity. The ovarian cancer tumor hypoxia causes the induction of CCL28 (HPA077434). The upregulated CCL28 accelerated tumor growth by binding to its cognate GPCR, CCR10 (HPA013819) and activation of the immunosuppressive regulatory T-cells (Tregs) <sup>35</sup>.




**Figure 8. Anti-CYSLTR2 antibody**

Immunohistochemical staining of human placenta using the **Anti-CYSLTR2 (HPA046528)** polyclonal antibody shows cytoplasmic and membranous positivity in trophoblastic cells, in brown.



**Figure 9. Anti-CCR7 antibody**

Immunofluorescent staining of human cell line A549 using the **Anti-CCR7 (HPA074467)** polyclonal antibody shows localization to mitochondria in green. Microtubules are shown in red and nuclei in blue.



**Figure 10. Anti-ADGRG5 antibody**

**A.** Immunohistochemistry analysis in human lymph node and placenta tissues using our **Anti-ADGRG5 (HPA007133)** polyclonal antibody. Corresponding RNA-seq data (TPM) are presented for the same tissues (orthogonal enhanced validation). **B.** Immunofluorescent staining of human cell line CACO-2 shows localization to nucleoplasm, nuclear membrane & vesicles, in green. Microtubules are shown in red and nuclei in blue.

**Table 1.**  
**FDA approved GPCRs drugs against different cancers.**

Receptor	Drug	Cancer Therapy	Approval
Dopamine receptor D1 (DRD1)	Cabergoline	Neuroendocrine tumors, pituitary tumors	1996
Somatostatin receptor (SSTR)	Lanreotide	Pancreatic cancer	2007
Gonadotropin releasing factor hormone receptor (GnRH)	Degarelix	Prostate cancer	2008
C-X-C chemokine receptor 4 (CXCR4)	Plerixafor	Multiple myeloma	2008
Smoothed receptor (SMO)	Vismodegib (Erivedge)	Locally advanced, and metastatic basal cell carcinoma	2012
Estrogen receptor (ER)	Raloxifene	Breast cancer	2014
Smoothed receptor (SMO)	Sonidegib	Locally advanced, and metastatic basal cell carcinoma	2015
C-C Chemokine receptor 4 (CCR4)	Mogamulizumab	T cell lymphoma	2018




## Box 2.

### GPR132, a potential tumor suppressor,

The early GPCR-derived oncogene G2A, also known as GPR132 (HPA029694, HPA029695), is a member of the proton-sensing GPCRs subfamily. This GPCR induces a full range of phenotypes characteristic of oncogenic cellular transformation of mouse fibroblasts and tumorigenicity<sup>36,37</sup>. Inhibition of GPR132 is a potentially novel treatment for reducing cancer metastasis. Loss of GPR132 in mice inhibits breast cancer metastasis, and lower GPR132 expression in patients with breast cancer correlates with better metastasis-free survival<sup>38</sup>.

### Figure 11. Anti-GPR132 antibody.

Immunohistochemical staining of a human colon with adenocarcinoma. The **Anti-GPR132 (HPA029695)** antibody binding is visible in brown.



## References

1. Thomsen et al., 2005 *Review Curr Opin Biotechnologies*, 16(6):655-65
2. Ma and Zimmel, 2002 *Nature Reviews Drug Discovery*, 1:571-72
3. Drews et al., 2000 *Science*, 287(5460):1960-4
4. Shoichet and Kobilka, 2012 *Trends in Pharmacological Sciences* 33(5): 268-272
5. Wu et al., 2019 *Review J Biol Chem*, 294(29):11062-11086
6. Young et al., 1986 *Cell*, 45(5):711-9
7. Santos-Otte et al., 2003 *Computational and Structural Biotechnology Journal*, 17: 1265-1277
8. Julius et al., 1989 *Science*, 244(4908):1057-62
9. Parma et al., 1993 *Nature*, 365(6447):649-51
10. Gutkind et al., 1991 *Proc Natl Acad Sci USA*, 88 (11) 4703-4707
11. Allen et al., 1991 *Proc Natl Acad Sci USA*, 88(24): 11354-11358
12. Ceraudo et al., 2020 *J Biol Chem*; 296:100163
13. Moreno et al., 2016 *Expert Opin Ther Targets*. 20(9): 1055-1073
14. Reubi et al., 2002 *Clin Cancer Res*. 8(4):1139-46.
15. Chave et al., 2000 *British Journal of Cancer*, 82:124-130
16. Sun et al., 2000 *Regul Pept*, 90(1-3):77-84
17. Wang et al., 2016 *Int. J. Mol. Sci.* 17(1), 95
18. Yi Zou et al., 2019 *Oncol Letters* 17(2): 1723-1731
19. Oddstig et al., 2011 *Cancer Biother Radiopharm* 26(6):759-65
20. Lehman et al., 2018 *Int. J. Cancer*, 144, 1104-1114
21. Holst et al., 2001 *J Clin Invest.*, 108(12):1789-96
22. Rinne et al., 2019 *Scientific Reports*, 9:7058
23. Tilan et al., 2013 *Oncotarget*, 4:2487-2501
24. Munoz et al., 2020 *Cancers*, 12(9): 2682.
25. Wim de Lau et al., 2014 *Review, Genes Dev*, 28(4):305-16.
26. Morgan et al., 2018 *Review, Br J Cancer*, 118(11):1410-1418
27. Gad and Balenga 2020 *ACS Pharmacol. Transl. Sci.*, 3, 1, 29-42
28. Chatterjee et al., 2021 *J Biol Chem*, 296:100261.
29. Zhang et al., 2019 *Mol Cancer Res.*, 17(11):2196-2207
30. Towner et al., 2013 *Neurosurgery*, 72(1):77-90
31. Bikfalvi and Billotet 2020 *Review, Am J Physiol Cell Physiol*. 318(3):C542-C554
32. Natsagdorj et al., 2019 *Cancer Sci.*, 110(1):279-288
33. Bonapace et al., 2014 *Nature*, 515(7525):130-3
34. Das et al., 2013 *J Exp Med.*, 210(8):1509-28.
35. Facciabene et al., 2011 *Nature*, 475(7355):226-30
36. Zohn et al., 2000 *Oncogene*, 19, 3866-3877
37. Obinata et al., 2009 *Prostaglandins & Other Lipid Mediators*, 89(3-4):66-72
38. Chen et al., 2016 *Proc Natl Acad Sci USA*, 114(3):580-585.

**Table 2**  
**Selection of polyclonal and monoclonal markers targeting GPCRs.**

Product Name	Alternative Gene Names	Product Number	Clonality	Validated Applications	Seq Identity mouse / rat
Anti-ACKR2	CCBP2, CCR10, CCR9	HPA013819	Polyclonal	IHC*	56% / 56%
Anti-ADGRG2	EDDM6, GPR64, HE6	HPA001478	Polyclonal	IHC*	78% / 78%
Anti-ADGRG2	EDDM6, GPR64, HE6	HPA050029	Polyclonal	IHC*, WB*	76% / 75%
Anti-ADGRG3	GPR97, Pb99, PGR26	AMAb91712	Monoclonal	WB	-
Anti-ADGRG3	GPR97, Pb99, PGR26	AMAb91713	Monoclonal	IHC*	-
Anti-ADGRG4	GPR112, PGR17	HPA035324	Polyclonal	IHC	79% / 27%
Anti-ADGRL4	ELTD1, ETL	AMAb91268	Monoclonal	IHC, WB	53% / 55%
Anti-ADGRE5	CD97, TM7LN1	HPA013707	Polyclonal	IHC*	49% / 51%
Anti-ADGRG5	GPR114, PGR27	HPA007133	Polyclonal	IHC*, ICC-IF	61% / 61%
Anti-ADGRG6	FLJ14937, GPR126	HPA017346	Polyclonal	IHC	55% / 53%
Anti-ADRA1B		HPA074416	Polyclonal	ICC-IF	96% / 94%
Anti-C2orf74	LOC339804	HPA026826	Polyclonal	IHC, ICC-IF	50% / 47%
Anti-CCL1	I-309, P500, SCYA1	HPA049861	Polyclonal	IHC	36% / 37%
Anti-CCL2	GDCF-2, HC11, MCAF	HPA019163	Polyclonal	IHC, ICC-IF	65% / 60%
Anti-CCL28	CCK1, MEC, SCYA28	HPA077434	Polyclonal	IHC	87% / 94%
Anti-CCR7	CD197, CDw197, CMKBR7	HPA031383	Polyclonal	ICC-IF	83% / 85%
Anti-CCR7	CD197, CDw197, CMKBR7	HPA074467	Polyclonal	ICC-IF	88% / 88%
Anti-CCR8	CMKBRL2, CY6, GPR-CY6	HPA042383	Polyclonal	IHC	50% / 58%
Anti-CHRM1		HPA014101	Polyclonal	IHC*	98% / 97%
Anti-CXCR3	CD183, CMKAR3, GPR9	HPA045942	Polyclonal	IHC*	67% / 67%
Anti-CXCR5	BLR1, CD185, MDR15	HPA042432	Polyclonal	IHC*	47% / 42%
Anti-CYSLTR2	CysLT(2), CYSLT2R	HPA046528	Polyclonal	IHC	35% / 37%
Anti-FPR2	FMLP-R-II, FMLPX, FPR2A	HPA029154	Polyclonal	IHC	63% / 63%
Anti-GPBAR1	GPCR, GPCR19, GPR131	HPA062890	Polyclonal	IHC*	82% / 75%
Anti-GPR4		HPA014278	Polyclonal	IHC	96% / 96%
Anti-GPR27	SREB1	HPA029395	Polyclonal	WB, ICC-IF	91% / 91%
Anti-GPR39		HPA022111	Polyclonal	IHC	55% / 54%
Anti-GPR132	G2A	HPA029694	Polyclonal	IHC	54% / 54%
Anti-GPR132	G2A	HPA029695	Polyclonal	IHC	36% / 42%
Anti-GPR143	OA1	HPA003648	Polyclonal	IHC*	55% / 55%
Anti-GPR162	A-2, GRCA	HPA055135	Polyclonal	IHC*, WB, ICC-IF	97% / 94%
Anti-GPR17		AMAb91624	Monoclonal	IHC*, WB	92% / 92%
Anti-GPR17		HPA029766	Polyclonal	IHC*	92% / 92%
Anti-GPR37L1	ETBR-LP-2	HPA064454	Polyclonal	IHC*	77% / 81%
Anti-GPR65	hTDAG8, TDAG8	HPA054454	Polyclonal	ICC-IF	61% / 63%
Anti-KNG1	BDK, BK, KNG	HPA001616	Polyclonal	IHC*, WB	62% / 61%
Anti-KNG1	BDK, BK, KNG	HPA001645	Polyclonal	IHC*, WB*	59% / 58%
Anti-LGR5	FEX, GPR49, GPR67, HG38	HPA012530	Polyclonal	IHC	88% / 87%
Anti-LRP6	ADCAD2	HPA029925	Polyclonal	IHC*	96% / 97%
Anti-MAS1L	dJ994E9.2, MAS-L, MRG	HPA017983	Polyclonal	IHC, ICC-IF	25% / 23%
Anti-NMUR2	NMU2R	HPA045836	Polyclonal	IHC	56% / 53%
Anti-SSTR1		HPA031506	Polyclonal	IHC	98% / 98%
Anti-SSTR2		HPA007264	Polyclonal	IHC, WB*, ICC-IF	98% / 96%
Anti-TACR1	NK1R, SPR, TAC1R	HPA074573	Polyclonal	IHC	100% / 100%
Anti-TACR2	NK2R, NK2AR, SKR, TAC2R	HPA076573	Polyclonal	ICC-IF	81% / 78%
Anti-TACR3	NK3R	HPA009418	Polyclonal	IHC	60% / 55%
Anti-TBXA2R		HPA077366	Polyclonal	ICC-IF	82% / 75%

\* Products with **enhanced validation** for indicated application.

In addition to the extensive validation and characterization always performed for our antibodies, we conduct application-specific **enhanced validation** to secure the antibody specificity in a defined context.



## VERY RELIABLE ANTIBODIES

Atlas Antibodies manufactures and provides over 21,000 highly validated monoclonal and polyclonal primary antibodies and control antigens targeting the majority of human proteins for tissue and cell analysis to explore and accelerate research in biology, pathology, and medicine. The portfolio covers different research areas such as neuroscience, cancer, cell biology, stem cell & development. All our products are rigorously evaluated for specificity, reproducibility and performance and characterized for use in IHC, WB, and ICC-IF. Enhanced validation is applied as an extra level of security of antibody specificity in a defined context. Available as 25 µL and 100 µL unit size.

## CREATED BY THE HUMAN PROTEIN ATLAS

With our roots in the Human Protein Atlas project, an integration of antibody-based imaging, proteomics, and transcriptomics, our antibodies are affinity-purified, reproducible, selective, and specific for their target proteins through our enhanced validation process. Our Triple A Polyclonals™ are developed within the Human Protein Atlas project.

## VALIDATED BY ENHANCED VALIDATION

We take great care to validate our antibodies in IHC, WB, and ICC-IF. Our antibodies are validated in all major human tissues and organs and 20 cancer tissues. Each antibody is supported by over 500 staining images. As an additional layer of security, we perform Enhanced Validation. By using 5 different enhanced validation methods we validate our antibodies for each combination of protein, sample, and application. Discover our Triple A Polyclonals™ and Precisa Monoclonals™ antibodies targeting the majority of human proteins in cells, tissues, and organs.

## EVIDENCED BY SCIENCE

Made by researchers for researchers our products are used all over the world and referenced in 1000s of scientific peer-reviewed papers.

## WE SUPPORT YOUR RESEARCH

Our scientific content and newsletter provide you with timely information about new product releases, research highlights, and much more. In addition, from our website you can download informative white papers, protocols, guides, posters, infographics, roundups of recent research papers, read blog posts and interviews.

## HOW TO BUY OUR PRODUCTS

Our products are available worldwide. We deliver to all destinations in Europe (excluding Russia), US, Canada, Australia, New Zealand and Israel. We expand our offering through trusted partners worldwide. You can **shop our full catalog online** or **find your local supplier**.



### Atlas Antibodies Advanced Polyclonals.

Triple A Polyclonals™ are rabbit polyclonal primary antibodies developed within the Human Protein Atlas project. IHC characterization data from 44 normal and 20 cancer tissues is available on the Human Protein Atlas portal.



### Precise. Accurate. Targeted.

Precisa Monoclonals™ are mouse monoclonal primary antibodies developed against a number of carefully selected targets. Clones are selected to recognize only unique non-overlapping epitopes and isotypes.

## PrEST Antigens

### Recombinant protein fragments

PrEST Antigens™ are used as immunogens for the generation of Triple A Polyclonals and Precisa Monoclonals.



Visit us: [atlasantibodies.com](https://atlasantibodies.com)

Follow us: [@atlasantibodies](https://twitter.com/atlasantibodies)

Contact us: [contact@atlasantibodies.com](mailto:contact@atlasantibodies.com)

Atlas Antibodies logo, Triple A Polyclonals, Precisa Monoclonals, and PrEST Antigen are trademarks or registered trademarks of Atlas Antibodies AB. All other trademarks are the property of their respective owners. Products are for research use only. Not for use in diagnostic procedures. © Atlas Antibodies AB 2022.

053\_20220317